US 10905752
VEGFR-2 targeting DNA vaccine for combination therapy
granted A61KA61K2039/505A61K2039/522
Quick answer
US patent 10905752 (VEGFR-2 targeting DNA vaccine for combination therapy) held by Vaximm AG expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vaximm AG
- Grant date
- Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K2039/522, A61K2039/523, A61K35/74